Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Clinical trial NCT03340766 · COMPLETED
Trial details
- NCT number
- NCT03340766
- Sponsor
- Amgen
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-16
- Primary completion
- 2020-11-06
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.